% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lfling:298230,
      author       = {L. L. Löfling and N. C. Støer and E. K. Sloan and S.
                      Nafisi and R. T. Fortner$^*$ and E. Botteri},
      title        = {{B}eta-blockers and epithelial ovarian cancer survival: {A}
                      {N}orwegian population-based cohort study.},
      journal      = {International journal of cancer},
      volume       = {157},
      number       = {1},
      issn         = {0020-7136},
      address      = {Bognor Regis},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2025-00237},
      pages        = {86-94},
      year         = {2025},
      note         = {2025 Jul 1;157(1):86-94},
      abstract     = {Cancer diagnosis and therapy cause stress to the body.
                      Preclinical studies have shown that stress hormones can
                      stimulate tumor progression and metastasis by interacting
                      with β-adrenergic receptors, and that β-blockers can
                      inhibit those processes. We assessed if β-blocker use was
                      associated with survival in a nationwide cohort of women
                      with epithelial ovarian cancer (EOC). We identified all
                      women aged ≥40 years who underwent EOC surgery in
                      2004-2018 in Norway through the Cancer Registry of Norway.
                      We estimated the association between peri-diagnostic and
                      post-diagnostic β-blocker use and survival. We used Cox
                      models, adjusted for sociodemographic and health factors,
                      and reported hazard ratios (HRs) and $95\%$ confidence
                      intervals (CIs). The difference in overall survival time
                      between β-blocker users and non-users was estimated as the
                      difference in restricted mean survival time at 5 years after
                      diagnosis using flexible parametric models. We included 3911
                      women with EOC; 540 $(14\%)$ used β-blockers at diagnosis,
                      1672 $(43\%)$ died of the disease, and 1882 $(48\%)$ died
                      overall. We found an association between peri-diagnostic
                      β-blocker use and longer EOC-specific survival (HR = 0.85,
                      $95\%CI$ 0.73-1.00; p-value = 0.048), and an indication of
                      an association with overall survival (HR = 0.89, $95\%CI$
                      0.77-1.02; p-value = 0.101). Analysis of post-diagnostic
                      β-blocker use, which included only women who survived 12
                      months or longer (n = 3344), found similar associations. At
                      5 years from diagnosis, peri-diagnostic β-blocker users
                      lived on average 1.28 months longer than non-users $(95\%CI$
                      0.01-2.60 months). The results support the hypothesis that
                      β-blocker use improves EOC-specific survival in women with
                      EOC.},
      keywords     = {beta‐blockers (Other) / ovarian cancer (Other) /
                      population‐based (Other) / registry (Other) / survival
                      (Other)},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39865612},
      doi          = {10.1002/ijc.35348},
      url          = {https://inrepo02.dkfz.de/record/298230},
}